Drug Trial Radar · NCT06181136
Study of DNL126 in Pediatric Participants With Mucopolysaccharidosis Type IIIA (Sanfilippo Syndrome Type A)
Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Dec 7, 2023
Primary completion
Jul 2032
Study completion Jul 2032
Sponsor
- Lead sponsor
- Denali Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 26, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 0 years, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, open-label, Phase 1/2 study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and clinical efficacy of DNL126 in participants with Sanfilippo syndrome Type A (MPS IIIA). In Part 1, the core study period is 25 weeks (approximately 6 months); followed by an open-label extension (OLE), which extends through Week 97 (approximately 18 months); and a long-term extension (LTE), which extends through Week 241 (Year 5). In Part 2, the core study period is 25 weeks in duration followed by an OLE, which extends through Week 49, and an LTE, which extends through Week 241 (Year 5). Participants with MPS IIIA will be enrolled in three planned cohorts, and additional participants with MPS IIIA may be enrolled in three optional cohorts. The study will enroll up to approximately 30 participants in total: 26 participants in Part 1 (Cohorts A1, A2, A3, B1, and B2 - not enrolling) and 4 participants in Part 2 (Cohort C1 - actively enrolling).
Conditions
- Mucopolysaccharidosis Type IIIA
Interventions
DNL126Drug
intravenous repeating dose
Prophylactic immunomodulatory therapyDrug
Per local prescribing information
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Change from baseline in the natural logarithm of cerebrospinal fluid (CSF) heparan sulfate (HS) concentrationTime frame: 49 weeks
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
UCSF Benioff Children's Hospital Oakland
Oakland, California · Recruiting
University of Iowa Stead Family Children's Hospital
Iowa City, Iowa · Recruiting
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina · Recruiting
Baylor College of Medicine and Texas Children's Hospital
Houston, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.